TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TGTX
Previous Symbol
CUSIPN/A
Phone212-554-4484
Debt
Debt-to-Equity RatioN/A
Current Ratio2.73
Quick Ratio3.68
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$150,000.00
Price / Sales2,956.77
Cash FlowN/A
Price / CashN/A
Book Value$0.87 per share
Price / Book6.15
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-118,470,000.00
Net Margins-99,001.33%
Return on Equity-185.20%
Return on Assets-127.26%
Miscellaneous
Employees75
Outstanding Shares82,900,000
Market Cap$428.58 million
OptionableOptionable
TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions
What is TG Therapeutics' stock symbol?
TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."
How were TG Therapeutics' earnings last quarter?
TG Therapeutics Inc (NASDAQ:TGTX) issued its quarterly earnings data on Friday, November, 9th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.12. The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 185.20% and a negative net margin of 99,001.33%. View TG Therapeutics' Earnings History.
When is TG Therapeutics' next earnings date?
What price target have analysts set for TGTX?
4 analysts have issued 12 month price targets for TG Therapeutics' stock. Their forecasts range from $12.00 to $27.00. On average, they anticipate TG Therapeutics' share price to reach $21.50 in the next year. This suggests a possible upside of 301.9% from the stock's current price. View Analyst Price Targets for TG Therapeutics.
What is the consensus analysts' recommendation for TG Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TG Therapeutics.
What are Wall Street analysts saying about TG Therapeutics stock?
Here are some recent quotes from research analysts about TG Therapeutics stock:
- 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (11/16/2018)
- 2. HC Wainwright analysts commented, "We are lowering our price target to $20, from $21, due to higher share count assumptions. Our $20 price target is based on the net present value of our revenue forecast through 2026, applying a 45% probability of success (POS) for ublituximab in CLL, a 45% POS for umbralisib in 25% POS for both ublituximab and umbralisib in NHL. We use a 4x price/sales multiple for these products, an early stage pipeline value of $2.84/share, and fully diluted net cash of $0.75/ share to arrive at our price target. Our P/S multiple of 4x is in-line with TG’s peers that range between 2-5x." (11/12/2018)
- 3. Raymond James analysts commented, "We are maintaining our Strong Buy rating for TG Therapeutics. Today, at the American Academy of Neurology (AAN) 70th Annual Meeting, the company provided an update on the ongoing Phase II study of TG-1101 (ublituximab) in patients with relapsing forms of multiple sclerosis (RMS)." (4/25/2018)
Has TG Therapeutics been receiving favorable news coverage?
Headlines about TGTX stock have trended positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TG Therapeutics earned a news sentiment score of 2.8 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of TG Therapeutics' key competitors?
Some companies that are related to TG Therapeutics include Ironwood Pharmaceuticals (IRWD), Aimmune Therapeutics (AIMT), Zogenix (ZGNX), Innoviva (INVA), Arena Pharmaceuticals (ARNA), Cambrex (CBM), PTC Therapeutics (PTCT), The Medicines (MDCO), G1 Therapeutics (GTHX), Enanta Pharmaceuticals (ENTA), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), TESARO (TSRO), Theravance Biopharma (TBPH) and Biohaven Pharmaceutical (BHVN).
Who are TG Therapeutics' key executives?
TG Therapeutics' management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 52)
- Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 36)
- Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
- Mr. Adam Waldman, Chief Commercial Officer
Who are TG Therapeutics' major shareholders?
TG Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.34%), FMR LLC (3.56%), Franklin Resources Inc. (2.29%), Highland Capital Management LP (0.91%), Candriam Luxembourg S.C.A. (0.84%) and Nexthera Capital LP (0.54%). Company insiders that own TG Therapeutics stock include Laurence N Charney, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics.
Which institutional investors are selling TG Therapeutics stock?
TGTX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, FMR LLC, Columbus Circle Investors, Franklin Resources Inc., Opaleye Management Inc., Jefferies Group LLC, Virtus ETF Advisers LLC and Credit Suisse AG. Company insiders that have sold TG Therapeutics company stock in the last year include Sean A Power and William James Kennedy. View Insider Buying and Selling for TG Therapeutics.
Which institutional investors are buying TG Therapeutics stock?
TGTX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Nexthera Capital LP, Highland Capital Management LP, Candriam Luxembourg S.C.A., Dimensional Fund Advisors LP, Claraphi Advisory Network LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for TG Therapeutics.
How do I buy shares of TG Therapeutics?
Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TG Therapeutics' stock price today?
One share of TGTX stock can currently be purchased for approximately $5.35.
How big of a company is TG Therapeutics?
TG Therapeutics has a market capitalization of $428.58 million and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-118,470,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. TG Therapeutics employs 75 workers across the globe.
What is TG Therapeutics' official website?
How can I contact TG Therapeutics?
TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]
MarketBeat Community Rating for TG Therapeutics (NASDAQ TGTX)
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
